

Acute coronary syndromes

S.D. Kristensen (Aarhus, DK)



Highlight Session
World Congress of Cardiology 2006
2-6 September - **Barcelona, Spain**



www.worldcardio.org

FRISC II study: five years follow-up

- The FRISC II trial compared an early invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome (NSTEMI-ACS).

B Lagerqvist, SE, 1743




Highlight Session
World Congress of Cardiology 2006
2-6 September - **Barcelona, Spain**



www.worldcardio.org

FRISC II: Death or MI during 5 year



Invasive	Noninv.	RR (95 % CI)	p
19.9 %	24.5 %	0.81 (0.69 - 0.95)	0.009

Highlight Session

World Congress of Cardiology 2006


2-6 September - Barcelona, Spain



www.worldcardio.org

FRISC II: Mortality during 5 years

Invasive	Non-inv.	RR (95 % CI)	p
9.7 %	10.1 %	0.95 (0.75 - 1.21)	0.69



Highlight Session

World Congress of Cardiology 2006

2-6 September - Barcelona, Spain



www.worldcardio.org

ICTUS trial: three years follow-up

1200 patients randomized to an early invasive strategy or to a more conservative (selectively invasive) strategy.

RJ De Winter, NL, 1743




Highlight Session
World Congress of Cardiology 2006
2-6 September - Barcelona, Spain




www.worldcardio.org

ICTUS – 3 years follow-up

Death, MI, Rehospitalization for ACS



All cause mortality



Highlight Session

World Congress of Cardiology 2006

2-6 September - Barcelona, Spain



www.worldcardio.org

NSTEMI – pending questions

- Optimal strategy and timing of invasive therapy
- Optimal anti-thrombotic therapy



Highlight Session
World Congress of Cardiology 2006
2-6 September - **Barcelona, Spain**



www.worldcardio.org

OASIS 5/6 combined

- OASIS-5 trial: **20,000 patients with NSTEMI-ACS** - non-inferiority of **fondaparinux** in direct, double blind comparison to **enoxaparin** at 9 days and a 50% reduction in major bleeding
- OASIS-6 trial: **12,000 patients with STEMI** - fondaparinux reduced death and MI with no increase in bleeding
- Aim: to determine the efficacy and safety of **fondaparinux** across the entire spectrum of acute coronary syndromes (STEMI and NSTEMI).

SR Mehta, CA, 1745




Highlight Session
World Congress of Cardiology 2006
2-6 September - **Barcelona, Spain**



www.worldcardio.org

UFH/Enox versus Fondaparinux Death/MI/Stroke at 30 days



Highlight Session

World Congress of Cardiology 2006


2-6 September - Barcelona, Spain



www.worldcardio.org

Major Bleeding at 30 days

UFH/Enox versus Fondaparinux



Highlight Session




World Congress of Cardiology 2006

2-6 September - Barcelona, Spain



www.worldcardio.org

STEMI: ExTRACT-TIMI 25



M Gibson, US, 1735




Highlight Session
World Congress of Cardiology 2006
2-6 September - Barcelona, Spain



www.worldcardio.org

PCI Cohort: Primary Endpoint Death or Nonfatal MI by 30 days



Highlight Session

World Congress of Cardiology 2006

2-6 September - Barcelona, Spain



www.worldcardio.org

PCI Cohort: Safety

Event	ENOX n=2,238	UFH n=2,377	RR	P-Value
TIMI Major Bleed	1.4%	1.6%	0.87 (0.55-1.39)	0.56
TIMI Minor Bleed	3.3%	2.4%	1.34 (0.95-1.88)	0.09
TIMI Major or Minor Bleed	4.6%	4.0%	1.15 (0.88-1.51)	0.31
ICH	0.2%	0.4%	0.42 (0.13-1.35)	0.18
Stroke	0.3%	0.9%	0.30 (0.12-0.75)	0.006

Highlight Session

World Congress of Cardiology 2006

2-6 September - Barcelona, Spain



www.worldcardio.org

PCI-ExTRACT-TIMI 25

Take-home-message

Enoxaparin after thrombolysis:

- if risk of bleeding is low and PCI is an option
- Continue on enoxaparin for PCI



Highlight Session
World Congress of Cardiology 2006
2-6 September - Barcelona, Spain



www.worldcardio.org

The Thrombolysis in Cardiac Arrest (TROICA) trial.

- 1,050 patients suffering from witnessed out-of-hospital arrest of presumed cardiac origin were randomly assigned to TNK or placebo, plus standard therapy for Cardiac Arrest.

BW Boettiger, DE, 3421




Highlight Session
World Congress of Cardiology 2006
2-6 September - Barcelona, Spain



www.worldcardio.org

TROICA: results



- Hospital admission (p=0.931)
- 30-day survival (p=0.512)

Highlight Session

World Congress of Cardiology 2006
2-6 September - Barcelona, Spain




www.worldcardio.org

TRANSIENT LEFT VENTRICULAR APICAL BALLOONING

Tako-Tsubo syndrome

Broken heart syndrome



3597, 3598, 3599, 3600, 3601, 3602



Highlight Session
World Congress of Cardiology 2006
2-6 September - **Barcelona, Spain**



www.worldcardio.org

TAKO-TSUBO syndrome

Bad news: emotions can break our hearts, and women are at increased risk

Good news: the syndrome seems to be benign with rapid full recovery of LV dysfunction

However: **further research is needed** (substrate, triggers, apical location, ...).

Fioretti PM, IT, 3599




Highlight Session
World Congress of Cardiology 2006
2-6 September - **Barcelona, Spain**



www.worldcardio.org

Tako-Tsubo syndrome



Thank you!

Kurisu S et al. Am Heart J, 2002; 143: 448-455



Highlight Session
World Congress of Cardiology 2006
2-6 September - Barcelona, Spain



www.worldcardio.org